{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:12:05Z","timestamp":1774296725853,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jagp.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T05:52:54Z","timestamp":1742449974000},"page":"819-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Add-On Agomelatine on Agitation, Aggression, and Neuroprotection in Alzheimer's Disease: A Randomized, Blinded, Controlled Trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Alireza","family":"Kargar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delara Hazegh","family":"Fetratjoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reihaneh","family":"Moattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahita","family":"Tarki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aram","family":"Golsokhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloufar","family":"Pouyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Amjadi-Goojgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamideh","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba","family":"Kakeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh Sadat","family":"Zendehbad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnam Safarpour","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Esmaily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Noroozian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2025.03.001_bib0001","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/alz.12901","article-title":"The worldwide costs of dementia in 2019","volume":"19","author":"Wimo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jagp.2025.03.001_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/B978-0-444-64012-3.00002-2","article-title":"Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia","volume":"165","author":"Deardorff","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0003","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3233\/JAD-201483","article-title":"Impact of dementia-related behavioral symptoms on healthcare resource use and caregiver burden: real-world data from Europe and the United States","volume":"81","author":"Chekani","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jagp.2025.03.001_bib0004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40501-020-00233-9","article-title":"Pharmacological management of neuropsychiatric symptoms of dementia","volume":"7","author":"Gerlach","year":"2020","journal-title":"Curr Treat Options Psychiatr"},{"key":"10.1016\/j.jagp.2025.03.001_bib0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0b013e3182a6096e","article-title":"Use and safety of antipsychotics in behavioral disorders in elderly people with dementia","volume":"34","author":"Gareri","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0006","unstructured":"U.S. Food and Drug Administration. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer\u2019s disease. 2023 [Accessed April 3, 2025]. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease."},{"key":"10.1016\/j.jagp.2025.03.001_bib0007","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.jagp.2025.03.001_bib0008","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jagp.2025.03.001_bib0009","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3389\/fnins.2020.00910","article-title":"Potential pathways for circadian dysfunction and sundowning-related behavioral aggression in Alzheimer's disease and related dementias","volume":"14","author":"Todd","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jagp.2025.03.001_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-012-2656-6","article-title":"The effect of agomelatine on 5HT (2C) receptors in humans: a clinically relevant mechanism?","volume":"221","author":"Norman","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jagp.2025.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1412901","DOI":"10.3389\/fpsyt.2024.1412901","article-title":"Neurobiological alteration in agitation in Alzheimer\u2019s disease and possible interventions","volume":"15","author":"Rao","year":"2024","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.jagp.2025.03.001_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw003","article-title":"Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms","volume":"19","author":"Martinotti","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.jagp.2025.03.001_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1874609816666230816090934","article-title":"Neuropsychiatric symptoms are related to blood-biomarkers in major neurocognitive disorders","volume":"17","author":"Marques-Aleixo","year":"2024","journal-title":"Curr Aging Sci"},{"key":"10.1016\/j.jagp.2025.03.001_bib0015","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"J. Am. Med. Assoc"},{"key":"10.1016\/j.jagp.2025.03.001_bib0016","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). [Published November 9, 2016. Accessed April 3, 2025]. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf."},{"key":"10.1016\/j.jagp.2025.03.001_bib0017","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s13760-021-01686-2","article-title":"Translation and psychometric evaluation of a Persian version of the functional assessment staging scale (I-FAST) in older patients with mild cognitive impairment and Alzheimer's disease in Iran","volume":"122","author":"Noroozian","year":"2022","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.jagp.2025.03.001_bib0018","unstructured":"International Psychogeriatric Association. The IPA complete guides to BPSD\u2014specialists guide. Module 5: non-pharmacological treatments. 2015 [Accessed April 3, 2025]. Available from:https:\/\/www.ipa-online.org\/UserFiles\/file\/IPA_BPSD_Specialists_Complete_Guide_Online_2015_FinaL.pdf"},{"key":"10.1016\/j.jagp.2025.03.001_bib0019","first-page":"67","article-title":"Azizeh AE: reliability, validity and factor analysis of Cohen-Mansfield agitation inventory (CMAI)","volume":"18","author":"Maryam","year":"2012","journal-title":"Iranian Journal of Psychiatr Clin Psychol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0020","doi-asserted-by":"crossref","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","article-title":"Rosenthal AS: a description of agitation in a nursing home","volume":"44","author":"Cohen-Mansfield","year":"1989","journal-title":"J Gerontol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0021","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/gps.2499","article-title":"Assessing neuropsychiatric symptoms in nursing home patients with dementia: reliability and Reliable Change Index of the Neuropsychiatric Inventory and the Cohen-Mansfield Agitation Inventory","volume":"26","author":"Zuidema","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2025.03.001_bib0022","unstructured":"Neuraxpharm UK Limited. Package leaflet: Information for the patient, Agomelatine 25 mg Film-coated tablets. Farnborough (UK): Medicines.org.uk; 2020 [Accessed September 23, 2024]. Available from: https:\/\/www.medicines.org.uk\/emc\/files\/pil.6564.pdf,"},{"key":"10.1016\/j.jagp.2025.03.001_bib0023","doi-asserted-by":"crossref","first-page":"701","DOI":"10.9758\/cpn.2022.20.4.701","article-title":"The effect of agomelatine in behavioral and psychological of dementia","volume":"20","author":"Wang","year":"2022","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.jagp.2025.03.001_bib0024","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front Psychol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1379062","article-title":"Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementia","volume":"15","author":"Meunier","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","article-title":"Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011-2022 update","volume":"40","author":"Rogowska","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jagp.2025.03.001_bib0027","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.jagp.2019.01.133","article-title":"Retrospectively assessing the efficacy of agomelatine in behavioral and psychological symptoms of dementia","volume":"27","author":"Wang","year":"2019","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.jagp.2025.03.001_bib0028","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","article-title":"Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease","volume":"17","author":"Gehrman","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2025.03.001_bib0029","first-page":"73","article-title":"Sundowning in dementia: clinical relevance, pathophysiological determinants, and therapeutic approaches","volume":"3","author":"Canevelli","year":"2016","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jagp.2025.03.001_bib0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4306\/pi.2011.8.4.275","article-title":"Sundown syndrome in persons with dementia: an update","volume":"8","author":"Khachiyants","year":"2011","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.jagp.2025.03.001_bib0031","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/agm2.12221","article-title":"Circadian dysfunction and Alzheimer's disease - an updated review","volume":"6","author":"Ahmad","year":"2023","journal-title":"Aging Med (Milton)"},{"key":"10.1016\/j.jagp.2025.03.001_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5533827","article-title":"Serotonin 2 receptors, agomelatine, and behavioral and psychological symptoms of dementia in Alzheimer's Disease","volume":"2021","author":"Li","year":"2021","journal-title":"Behav Neurol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0033","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0167-4943(00)00068-6","article-title":"Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study","volume":"31","author":"Cohen-Mansfield","year":"2000","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.jagp.2025.03.001_bib0034","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/01.jcp.0000132443.12607.fd","article-title":"Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy","volume":"24","author":"Mahlberg","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jagp.2025.03.001_bib0035","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/sleep\/26.7.893","article-title":"A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease","volume":"26","author":"Singer","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.jagp.2025.03.001_bib0036","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1272\/jnms.70.334","article-title":"Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia","volume":"70","author":"Asayama","year":"2003","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.jagp.2025.03.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/640389","article-title":"Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction","volume":"2012","author":"Hardeland","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.jagp.2025.03.001_bib0038","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1074\/jbc.M114.559542","article-title":"Convergence of melatonin and serotonin (5-HT) signaling at MT2\/5-HT2C receptor heteromers","volume":"290","author":"Kamal","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jagp.2025.03.001_bib0039","article-title":"Agomelatine prevents amyloid plaque deposition, tau phosphorylation, and neuroinflammation in APP\/PS1 mice","volume":"13","author":"Yang","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.jagp.2025.03.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1412901","article-title":"Neurobiological alteration in agitation in Alzheimer's disease and possible interventions","volume":"15","author":"Rao","year":"2024","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.jagp.2025.03.001_bib0041","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40263-016-0351-6","article-title":"Characterisation of agomelatine-induced increase in liver enzymes: frequency and risk factors determined from a pooled analysis of 7605 treated patients","volume":"30","author":"Perlemuter","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jagp.2025.03.001_bib0042","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrd3140","article-title":"Agomelatine, the first melatonergic antidepressant: discovery, characterization and development","volume":"9","author":"de Bodinat","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jagp.2025.03.001_bib0043","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00429-017-1439-6","article-title":"Melatonin receptors: distribution in mammalian brain and their respective putative functions","volume":"222","author":"Ng","year":"2017","journal-title":"Brain Structure Function"},{"issue":"12","key":"10.1016\/j.jagp.2025.03.001_bib0044","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3390\/ijms20122925","article-title":"Effect of the 5-HT2C Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study","volume":"20","author":"Whitestone","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jagp.2025.03.001_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11920-020-01208-6","article-title":"Understanding brain mechanisms of reactive aggression","volume":"22","author":"Bertsch","year":"2020","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jagp.2025.03.001_bib0046","first-page":"121","article-title":"Distribution of 5-HT receptors in the central nervous system: An update","volume":"31","author":"Vilar\u00f3","year":"2020"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S106474812500082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S106474812500082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:07:28Z","timestamp":1767010048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S106474812500082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S106474812500082X"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2025.03.001","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Add-On Agomelatine on Agitation, Aggression, and Neuroprotection in Alzheimer's Disease: A Randomized, Blinded, Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}